VIVXF News and Press, Avivagen From 06/21/22

Q2 Results. Avivagen reported revenue of $88,438 (all figures are in Canadian $), down from $159,614 the prior year and below our estimate of $400,000. Net loss for the quarter was at $1.3 million or $0.02 per share, an increase over the prior year's $2.2 million or $0.04 per share, and better...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

Safety Studies. Avivagen completed a series of safety evaluations based on the oxidized beta-carotene (OxBC), a critical active ingredient in the OxC-beta product line. Results of the Avivagen-initiated toxicology study, conducted following standardized and internationally recognized protocols...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

New Distributor. Avivagen's management recently announced the Company has signed a new distribution agreement with Nong San Viet Co. to support the continued expansion of Avivagen's OxC-beta feed additive. No details were given on the length of the agreement. We believe that this new distribut...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

China Approval. Avivagen's oxidized carotenoid-based feed additive, OxC-beta, has received approval for use in China. This is a significant accomplishment for Avivagen and should have a positive impact on operating results going forward. China marks the second key market, along with Vietnam, i...

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...

Record Year of Progress for OxC-beta TM Adoption Worldwide Supply agreement with AB Vista in United States, Brazil and Thailand compliments existing partnerships in Asia and Mexico Continued positive animal trial results leading to orders, new customer wins...